USA — FUJIFILM Diosynth Biotechnologies, a prominent contract development and manufacturing organization (CDMO), has introduced a groundbreaking Strategic Business Unit (SBU) structure.
This pioneering approach aims to provide tailored and top-tier support to biopharmaceutical customers of all scales, underpinned by specialized service offerings and manufacturing capacities.
The strategic overhaul includes two distinct SBUs – one focusing on large-scale operations and the other on small-scale services.
This strategic reconfiguration comes with a team of seasoned leaders at the helm, poised to steer the company toward enhanced customer satisfaction and future growth.
FUJIFILM Diosynth Biotechnologies is revolutionizing its business model through the introduction of a Strategic Business Unit (SBU) framework.
This innovative structure is designed to offer precise and customized support to a diverse array of biopharmaceutical clients.
By aligning unique service offerings and manufacturing capabilities, the SBU approach aims to deliver high-quality service and performance, regardless of the scale of the operations.
Catering for diverse needs
The new business approach consists of two core SBUs, each catering to distinct needs within the biopharmaceutical sector.
The large-scale SBU is strategically designed to address the requirements of clients seeking high-volume cell culture production.
This SBU is equipped with advanced 20,000 L bioreactors, offering unparalleled efficiency and throughput.
On the other hand, the small-scale SBU focuses on supporting clients navigating the intricacies of the regulatory landscape, spanning pre-clinical to commercial production stages.
Bioreactors ranging from 200 L to 2,000 L, along with single-use manufacturing systems, facilitate operations in this domain.
Dynamic leadership
Kenneth Bilenberg will lead the large-scale SBU, overseeing biopharmaceutical manufacturing activities across multiple sites.
With over two decades of leadership experience in the life science and biotechnology sectors, Bilenberg brings proven expertise to his role.
Lee Kingsbury, an industry veteran with an extensive leadership track record, will head the small-scale SBU. This unit encompasses a range of services for biologics, cell and gene therapies, and viral vaccines.
Peter Dam Madsen will steer the newly established Strategy & Executive Office, guiding global business strategy and key initiatives.
The implementation of the SBU model reflects FUJIFILM Diosynth’s commitment to innovation and superior service.
This strategic shift is set to drive mutual growth opportunities and foster partnerships that maximize efficiency across the network.
The company’s visionary leadership, including Toshi Iida and Lars Petersen, expresses confidence in the newly established framework’s ability to cultivate customer success and contribute to the development of groundbreaking treatments.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
